23andMe (NASDAQ:ME) Given Sell (E+) Rating at Weiss Ratings

23andMe (NASDAQ:ME)‘s stock had its “sell (e+)” rating reiterated by equities researchers at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

23andMe Stock Down 2.9 %

NASDAQ ME opened at $2.72 on Wednesday. The company has a market capitalization of $72.98 million, a price-to-earnings ratio of -0.18 and a beta of 1.14. 23andMe has a twelve month low of $2.42 and a twelve month high of $15.22. The stock has a fifty day simple moving average of $3.23 and a 200 day simple moving average of $4.70.

23andMe (NASDAQ:ME) last posted its quarterly earnings data on Tuesday, January 28th. The company reported ($1.02) earnings per share for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.

Institutional Trading of 23andMe

A number of large investors have recently bought and sold shares of the business. FNY Investment Advisers LLC acquired a new stake in 23andMe during the 4th quarter worth about $26,000. Leavell Investment Management Inc. acquired a new stake in 23andMe during the 4th quarter worth about $32,000. MassMutual Private Wealth & Trust FSB acquired a new stake in 23andMe during the 4th quarter worth about $40,000. Virtu Financial LLC acquired a new stake in 23andMe during the 4th quarter worth about $49,000. Finally, Geode Capital Management LLC boosted its position in shares of 23andMe by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock worth $1,476,000 after purchasing an additional 28,252 shares in the last quarter. 36.10% of the stock is currently owned by institutional investors and hedge funds.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.